Recombinant Human IL-17RE Protein (C-Fc)

Beta LifeScience SKU/CAT #: BL-2747NP
BL-2747NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
BL-2747NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Recombinant Human IL-17RE Protein (C-Fc)

Beta LifeScience SKU/CAT #: BL-2747NP

Collections: Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human Interleukin-17 Receptor E is produced by our Mammalian expression system and the target gene encoding Thr155-His454 is expressed with a human IgG1 Fc tag at the C-terminus.
Accession Q8NFR9
Synonym IL-17 RE; IL-17 receptor E; IL17RE; IL-17RE; interleukin 17 receptor E
Gene Background Interleukin 17 Receptor E (IL 17 RE) is an approximately 70 kDa (predicted) transmembrane protein in the family of IL 17 receptors. IL 17 RE is expressed on keratinocytes, mucosal epithelial cells, Th17 cells, and gamma /δ T cells. It associates with the widely expressed IL 17 RA to form a heterodimeric receptor for IL-17C. IL-17C binds to IL 17 RE with high affinity and to IL 17 RA with low affinity. IL 17C expression is induced by inflammatory stimulation in colon and airway epithelial cells, keratinocytes, CD4+ T cells, macrophages, and dendritic cells. It is up regulated in various chronic inflammatory diseases including psoriasis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD). IL 17 RE is reciprocally down regulated in psoriatic lesions. The interaction of IL 17C with IL 17 RE promotes mucosal immunity through the induction of anti bacterial peptides and pro inflammatory cytokines and chemokines. IL 17C action supports the integrity of the colon epithelium following infection induced damage but also contributes to psoriatic skin thickening and the progression of arthritis. IL 17C is additionally up regulated in Th17 cell dependent autoimmunity. In this setting, it exacerbates disease severity by inducing Th17 cell production of IL 17A, IL 17F, IL 22, CCR6, and CCL20. The up regulation of IL 17 RE in hepatocellular carcinoma is associated with poor prognosis.
Molecular Mass 61 KDa
Apmol Mass 60-75 KDa, reducing conditions
Formulation Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
Endotoxin Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity Not tested
Reconstitution Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below.
Usage For Research Use Only

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed